# Reversing the irreversible? A case of successful surgical repair in a late-presenting aortopulmonary window with severe pulmonary hypertension

**Authors:** Rido Mulawarman, Ericko Ongko Joyo, Muhamad Adrin Aefiansyah Putra, Aditya Agita Sembiring, Sisca Natalia Siagian, Oktavia Lilyasari

PMC · DOI: 10.1186/s43044-026-00726-7 · The Egyptian Heart Journal · 2026-03-09

## TL;DR

A teenager with a rare heart defect and severe lung pressure was successfully treated with drugs and surgery after initial tests suggested it was untreatable.

## Contribution

Demonstrates that late surgical repair of aortopulmonary window with severe pulmonary hypertension may be possible through medical preconditioning and serial hemodynamic assessment.

## Key findings

- Targeted medical therapy reduced pulmonary vascular resistance significantly in a 15-year-old with a large aortopulmonary window.
- Serial hemodynamic reassessment revealed latent pulmonary vasoreactivity not detected in initial testing.
- Successful surgical repair was achieved despite initial indications of inoperability due to severe pulmonary hypertension.

## Abstract

Aortopulmonary window (APW) is a rare congenital heart defect, accounting for only 0.2–0.6% of all congenital cardiac anomalies, and is usually identified and surgically corrected within the first year of life to prevent irreversible pulmonary hypertension (PH). Once pulmonary vascular resistance (PVR) becomes fixed, surgical repair is generally considered contraindicated. However, emerging evidence suggests that pulmonary vascular reactivity may persist in select adolescents, opening a potential therapeutic window beyond infancy.

We report a 15-year-old male with a large APW diagnosed in infancy but lost to follow-up, who presented in adolescence with exertional dyspnea. Initial cardiac catheterization revealed a high indexed PVR (10.89 WU·m²) and absent oxygen vasoreactivity, indicating inoperability. Despite this, preserved biventricular function and lack of cyanosis prompted a trial of targeted medical therapy with sildenafil, spironolactone, lisinopril, and digoxin. After 12 months, repeat catheterization showed dramatic haemodynamic improvement: baseline PVRi decreased to 8.84 WU·m² and fell further to 0.76 WU·m² after 100% oxygen, with a reduction in PVR/SVR ratio from 0.58 to 0.04. The calculated Qp/Qs increased to 16.77, although this extreme value was considered likely overestimated because systemic and pulmonary arterial oxygen saturations were almost identical. Definitive surgical repair was undertaken with excellent early results. On follow-up, the patient remained asymptomatic with preserved biventricular function, low estimated pulmonary artery pressures and no residual APW on echocardiography.

This case suggests that operability in APW may not be irrevocably lost beyond infancy in carefully selected adolescents. It underscores the importance of individualized assessment, medical preconditioning and serial haemodynamic reassessment to unmask latent pulmonary vasoreactivity. Larger series are needed to define which late-presenting patients with APW and PH may safely benefit from definitive surgical repair.

Operability in late-presenting APW is not always lost—Even in adolescents with severe pulmonary hypertension and absent initial vasoreactivity, pulmonary vascular reactivity may persist and can be unmasked with targeted medical therapy and serial reassessment.Medical preconditioning can reverse inoperability—Structured use of pulmonary vasodilators and supportive therapy prior to surgery can significantly reduce pulmonary vascular resistance, allowing safe definitive repair.Dynamic individualized assessment is essential—Single-point hemodynamic measurements may underestimate vascular adaptability; repeated evaluations and multidisciplinary decision-making should guide operability in complex congenital heart disease.

Operability in late-presenting APW is not always lost—Even in adolescents with severe pulmonary hypertension and absent initial vasoreactivity, pulmonary vascular reactivity may persist and can be unmasked with targeted medical therapy and serial reassessment.

Medical preconditioning can reverse inoperability—Structured use of pulmonary vasodilators and supportive therapy prior to surgery can significantly reduce pulmonary vascular resistance, allowing safe definitive repair.

Dynamic individualized assessment is essential—Single-point hemodynamic measurements may underestimate vascular adaptability; repeated evaluations and multidisciplinary decision-making should guide operability in complex congenital heart disease.

## Linked entities

- **Chemicals:** sildenafil (PubChem CID 135398744), spironolactone (PubChem CID 5833), lisinopril (PubChem CID 5362119), digoxin (PubChem CID 2724385)
- **Diseases:** pulmonary hypertension (MONDO:0005149), aortopulmonary window (MONDO:0021902)

## Full-text entities

- **Genes:** NR3C2 (nuclear receptor subfamily 3 group C member 2) [NCBI Gene 4306] {aka MCR, MLR, MR, NR3C2VIT}, F2R (coagulation factor II thrombin receptor) [NCBI Gene 2149] {aka CF2R, HTR, PAR-1, PAR1, TR}, NPPB (natriuretic peptide B) [NCBI Gene 4879] {aka BNP, Iso-ANP}
- **Diseases:** Eisenmenger (MESH:D004541), congenital heart defect (MESH:D006330), pulmonary vascular occlusive disease (MESH:D011668), vascular remodelling (MESH:D066253), failure to thrive (MESH:D005183), PH (MESH:D006976), intracardiac defects (MESH:C538262), pre-capillary disease (MESH:D058070), cardiomegaly (MESH:D006332), parenchymal lung disease (MESH:D017563), heart failure (MESH:D006333), tricuspid regurgitation (MESH:D014262), ASD (MESH:D001321), dyspnea (MESH:D004417), lung disease (MESH:D008171), pulmonary vascular disease (MESH:D014652), cyanosis (MESH:D003490), APW (MESH:C537782), atrial septal defect (MESH:D006344), inflammatory (MESH:D007249), mitral regurgitation (MESH:D008944), pulmonary regurgitation (MESH:D011665), congenital cardiac anomalies (MESH:C535853), shunt lesions (MESH:C562451), LV volume overload (MESH:D018487)
- **Chemicals:** iloprost (MESH:D016285), sildenafil (MESH:D000068677), digoxin (MESH:D004077), Spironolactone (MESH:D013148), oxygen (MESH:D010100), IMPRA (MESH:C078892), nitric oxide (MESH:D009569), lisinopril (MESH:D017706)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12972493/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12972493/full.md

---
Source: https://tomesphere.com/paper/PMC12972493